The DOI matches its Crossref record; 209 of the 209 references it cites were found in a registry or an index.
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Open accessAbstract
Cancer immunotherapy, as a paradigm shift in cancer treatment, has recently received tremendous attention. The active cancer vaccination, immune checkpoint blockage (ICB) and chimeric antigen receptor (CAR) for T‐cell‐based adoptive cell transfer are among these developments that have achieved a significant increase in patient survival in clinical trials. Despite these advancements, emerging research at the interdisciplinary interface of cancer biology, immunology, bioengineering, and materials science is important to further enhance the therapeutic benefits and reduce side effects. Here, an overview of the latest studies on engineering biomaterials for the enhancement of anticancer immunity is given, including the perspectives of delivery of immunomodulatory therapeutics, engineering immune cells, and constructing immune‐modulating scaffolds. The opportunities and challenges in this field are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Designing hydrogels for controlled drug delivery
Li, J., & Mooney, D. J. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.71 · Cited by 4,832
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Microneedles for drug and vaccine delivery
Kim, Y.-C., Park, J.-H., & Prausnitz, M. R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.04.005 · Cited by 1,760
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
Contribution of platelets to tumour metastasis
Gay, L. J., & Felding-Habermann, B. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3004 · Cited by 1,645
Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,596
Self-citationToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,350
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Nanoparticles target distinct dendritic cell populations according to their size
Manolova, V., Flace, A., Bauer, M., Schwarz, K., Saudan, P., & Bachmann, M. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200737984 · Cited by 1,289
Dendritic cells as therapeutic vaccines against cancer
Banchereau, J., & Palucka, A. K. (2005) · Nature Reviews Immunology · doi:10.1038/nri1592 · Cited by 1,204
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Cancer immunoediting from immune surveillance to immune escape
Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,074
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Designer vaccine nanodiscs for personalized cancer immunotherapy
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A., & Moon, J. J. (2017) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,056
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
Programming the magnitude and persistence of antibody responses with innate immunity
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 975
Dissolving polymer microneedle patches for influenza vaccination
Sullivan, S. P., Koutsonanos, D. G., del Pilar Martin, M., Lee, J. W., Zarnitsyn, V., Choi, S.-O., Murthy, N., Compans, R. W., Skountzou, I., & Prausnitz, M. R. (2010) · Nature Medicine · doi:10.1038/nm.2182 · Cited by 948
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Yu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., Ranson, D., Ligler, F. S., Buse, J. B., & Gu, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505405112 · Cited by 848
Self-citationThe role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H., & Gu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b05030 · Cited by 784
Self-citationHe, C., Duan, X., Guo, N., Chan, C., Poon, C., Weichselbaum, R. R., & Lin, W. (2016) · Nature Communications · doi:10.1038/ncomms12499 · Cited by 754
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Tacken, P. J., de Vries, I. J. M., Torensma, R., & Figdor, C. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2173 · Cited by 750
Therapeutic cell engineering with surface-conjugated synthetic nanoparticles
Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A., & Irvine, D. J. (2010) · Nature Medicine · doi:10.1038/nm.2198 · Cited by 750
Emerging roles for platelets as immune and inflammatory cells
Morrell, C. N., Aggrey, A. A., Chapman, L. M., & Modjeski, K. L. (2014) · Blood · doi:10.1182/blood-2013-11-462432 · Cited by 735
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.011 · Cited by 721
Stromal cells in tumor microenvironment and breast cancer
Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., & Wang, J. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9415-3 · Cited by 671
Adoptive-cell-transfer therapy for the treatment of patients with cancer
Dudley, M. E., & Rosenberg, S. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1167 · Cited by 660
Toxicities of Immunotherapy for the Practitioner
Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0379 · Cited by 650
Niikura, K., Matsunaga, T., Suzuki, T., Kobayashi, S., Yamaguchi, H., Orba, Y., Kawaguchi, A., Hasegawa, H., Kajino, K., Ninomiya, T., et al. (2013) · ACS Nano · doi:10.1021/nn3057005 · Cited by 638
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
Self-citationKim, S. E., Zhang, L., Ma, K., Riegman, M., Chen, F., Ingold, I., Conrad, M., Turker, M. Z., Gao, M., Jiang, X., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.164 · Cited by 622
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Gubin, M. M., Artyomov, M. N., Mardis, E. R., & Schreiber, R. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80008 · Cited by 613
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594
Impact of the physical microenvironment on tumor progression and metastasis
Spill, F., Reynolds, D. S., Kamm, R. D., & Zaman, M. H. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.007 · Cited by 581
Neutrophils in the tumor microenvironment
Powell, D. R., & Huttenlocher, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.11.008 · Cited by 578
Wang, C., Xu, L., Liang, C., Xiang, J., Peng, R., & Liu, Z. (2014) · Advanced Materials · doi:10.1002/adma.201402996 · Cited by 566
Self-citationRegulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
Moon, J. J., Suh, H., Bershteyn, A., Stephan, M. T., Liu, H., Huang, B., Sohail, M., Luo, S., Ho Um, S., Khant, H., et al. (2011) · Nature Materials · doi:10.1038/nmat2960 · Cited by 564
Vaccine delivery using nanoparticles
Gregory, A. E., Titball, R., & Williamson, D. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00013 · Cited by 561
Kim, J., Li, W. A., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 541
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 526
Self-citationMoynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J. M., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 524
Nurden, A. (2008) · Frontiers in Bioscience · doi:10.2741/2947 · Cited by 520
A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy
Cho, N.-H., Cheong, T.-C., Min, J. H., Wu, J. H., Lee, S. J., Kim, D., Yang, J.-S., Kim, S., Kim, Y. K., & Seong, S.-Y. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.149 · Cited by 514
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, S. M., Demento, S. L., Agawu, A., Licona Limon, P., et al. (2012) · Nature Materials · doi:10.1038/nmat3355 · Cited by 494
Cancer and the tumor microenvironment: a review of an essential relationship
Mbeunkui, F., & Johann, D. J. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0881-9 · Cited by 487
In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
Lizotte, P. H., Wen, A. M., Sheen, M. R., Fields, J., Rojanasopondist, P., Steinmetz, N. F., & Fiering, S. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.292 · Cited by 485
Neoantigen landscape dynamics during human melanoma–T cell interactions
Verdegaal, E. M. E., de Miranda, N. F. C. C., Visser, M., Harryvan, T., van Buuren, M. M., Andersen, R. S., Hadrup, S. R., van der Minne, C. E., Schotte, R., Spits, H., et al. (2016) · Nature · doi:10.1038/nature18945 · Cited by 461
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Kochenderfer, J. N., & Rosenberg, S. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 451
Processing Pathway Dependence of Amorphous Silica Nanoparticle Toxicity: Colloidal vs Pyrolytic
Zhang, H., Dunphy, D. R., Jiang, X., Meng, H., Sun, B., Tarn, D., Xue, M., Wang, X., Lin, S., Ji, Z., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja304907c · Cited by 446
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441
Lynn, G. M., Laga, R., Darrah, P. A., Ishizuka, A. S., Balaci, A. J., Dulcey, A. E., Pechar, M., Pola, R., Gerner, M. Y., Yamamoto, A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3371 · Cited by 440
Biopolymer implants enhance the efficacy of adoptive T-cell therapy
Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2015) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 439
Liang, C., Xu, L., Song, G., & Liu, Z. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00458j · Cited by 435
Infection-mimicking materials to program dendritic cells in situ
Ali, O. A., Huebsch, N., Cao, L., Dranoff, G., & Mooney, D. J. (2009) · Nature Materials · doi:10.1038/nmat2357 · Cited by 434
Cell-Based Therapeutics: The Next Pillar of Medicine
Fischbach, M. A., Bluestone, J. A., & Lim, W. A. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005568 · Cited by 419
Injectable cryogel-based whole-cell cancer vaccines
Bencherif, S. A., Warren Sands, R., Ali, O. A., Li, W. A., Lewin, S. A., Braschler, T. M., Shih, T.-Y., Verbeke, C. S., Bhatta, D., Dranoff, G., et al. (2015) · Nature Communications · doi:10.1038/ncomms8556 · Cited by 416
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
Targeting dendritic cells with biomaterials: developing the next generation of vaccines
Reddy, S. T., Swartz, M. A., & Hubbell, J. A. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.10.005 · Cited by 406
Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity
Flach, T. L., Ng, G., Hari, A., Desrosiers, M. D., Zhang, P., Ward, S. M., Seamone, M. E., Vilaysane, A., Mucsi, A. D., Fong, Y., et al. (2011) · Nature Medicine · doi:10.1038/nm.2306 · Cited by 405
Mitragotri, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1728 · Cited by 395
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Hanson, M. C., Crespo, M. P., Abraham, W., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 381
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 365
Radiotherapy: Changing the Game in Immunotherapy
Demaria, S., Coleman, C. N., & Formenti, S. C. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.002 · Cited by 363
Sul, J., Blumenthal, G. M., Jiang, X., He, K., Keegan, P., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0498 · Cited by 359
Hydrogels and Scaffolds for Immunomodulation
Singh, A., & Peppas, N. A. (2014) · Advanced Materials · doi:10.1002/adma.201402105 · Cited by 355
Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody
Wang, C., Sun, W., Wright, G., Wang, A. Z., & Gu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201506312 · Cited by 344
Self-citationYe, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z. (2016) · ACS Nano · doi:10.1021/acsnano.6b04989 · Cited by 339
Self-citationActive targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells
Huang, B., Abraham, W. D., Zheng, Y., Bustamante López, S. C., Luo, S. S., & Irvine, D. J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5447 · Cited by 312
Storni, T., Ruedl, C., Schwarz, K., Schwendener, R. A., Renner, W. A., & Bachmann, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1777 · Cited by 286
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Makkouk, A., & Weiner, G. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2538 · Cited by 285
Xu, Z., Wang, Y., Zhang, L., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn500216y · Cited by 284
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
Goldberg, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.037 · Cited by 278
Polymer multilayer tattooing for enhanced DNA vaccination
DeMuth, P. C., Min, Y., Huang, B., Kramer, J. A., Miller, A. D., Barouch, D. H., Hammond, P. T., & Irvine, D. J. (2013) · Nature Materials · doi:10.1038/nmat3550 · Cited by 277
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Fan, Y., & Moon, J. (2015) · Vaccines · doi:10.3390/vaccines3030662 · Cited by 275
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 271
Enhancing cell therapies from the outside in: Cell surface engineering using synthetic nanomaterials
Stephan, M. T., & Irvine, D. J. (2011) · Nano Today · doi:10.1016/j.nantod.2011.04.001 · Cited by 266
Wang, Y., Lin, Y.-X., Qiao, S.-L., An, H.-W., Ma, Y., Qiao, Z.-Y., Rajapaksha, R. P. Y. J., & Wang, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.034 · Cited by 266
Munn, D. H., & Mellor, A. L. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.11.003 · Cited by 259
Immunomodulatory spherical nucleic acids
Radovic-Moreno, A. F., Chernyak, N., Mader, C. C., Nallagatla, S., Kang, R. S., Hao, L., Walker, D. A., Halo, T. L., Merkel, T. J., Rische, C. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502850112 · Cited by 259
Targeting T cell metabolism for therapy
O'Sullivan, D., & Pearce, E. L. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.004 · Cited by 254
de Titta, A., Ballester, M., Julier, Z., Nembrini, C., Jeanbart, L., van der Vlies, A. J., Swartz, M. A., & Hubbell, J. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313152110 · Cited by 254
In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice
Ali, O. A., Emerich, D., Dranoff, G., & Mooney, D. J. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000359 · Cited by 246
Jewell, C. M., Bustamante López, S. C., & Irvine, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105200108 · Cited by 245
Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells
Sunshine, J. C., Perica, K., Schneck, J. P., & Green, J. J. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.050 · Cited by 244
Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design
Plummer, E. M., & Manchester, M. (2011) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.119 · Cited by 237
Perica, K., Tu, A., Richter, A., Bieler, J. G., Edidin, M., & Schneck, J. P. (2014) · ACS Nano · doi:10.1021/nn405520d · Cited by 236
Xiang, J., Xu, L., Gong, H., Zhu, W., Wang, C., Xu, J., Feng, L., Cheng, L., Peng, R., & Liu, Z. (2015) · ACS Nano · doi:10.1021/acsnano.5b02014 · Cited by 230
Self-citationManaging toxicities of high-dose interleukin-2.
Schwartz, R. N., Stover, L. L., & Dutcher, J. P. (2002) · PubMed · Cited by 229
Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells
Eggermont, L. J., Paulis, L. E., Tel, J., & Figdor, C. G. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.06.007 · Cited by 217
Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles
Stephan, M. T., Stephan, S. B., Bak, P., Chen, J., & Irvine, D. J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.029 · Cited by 209
Carpentier, A., Metellus, P., Ursu, R., Zohar, S., Lafitte, F., Barrie, M., Meng, Y., Richard, M., Parizot, C., Laigle-Donadey, F., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop047 · Cited by 206
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity
Li, Y., Fang, M., Zhang, J., Wang, J., Song, Y., Shi, J., Li, W., Wu, G., Ren, J., Wang, Z., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1074374 · Cited by 203
Goldinger, S. M., Dummer, R., Baumgaertner, P., Mihic‐Probst, D., Schwarz, K., Hammann‐Haenni, A., Willers, J., Geldhof, C., Prior, J. O., Kündig, T. M., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201142361 · Cited by 201
Fransen, M. F., van der Sluis, T. C., Ossendorp, F., Arens, R., & Melief, C. J. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0781 · Cited by 200
Kwong, B., Gai, S. A., Elkhader, J., Wittrup, K. D., & Irvine, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3343 · Cited by 197
The ABCs of artificial antigen presentation
Kim, J. V., Latouche, J.-B., Rivière, I., & Sadelain, M. (2004) · Nature Biotechnology · doi:10.1038/nbt955 · Cited by 192
Steenblock, E. R., & Fahmy, T. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.11 · Cited by 187
Meyer, R. A., Sunshine, J. C., Perica, K., Kosmides, A. K., Aje, K., Schneck, J. P., & Green, J. J. (2015) · Small · doi:10.1002/smll.201402369 · Cited by 183
FRAZER, I., QUINN, M., NICKLIN, J., TAN, J., PERRIN, L., NG, P., OCONNOR, V, WHITE, O., WENDT, N., & MARTIN, J. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.05.013 · Cited by 176
Kwong, B., Liu, H., & Irvine, D. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.067 · Cited by 175
The role of microneedles for drug and vaccine delivery
Quinn, H. L., Kearney, M.-C., Courtenay, A. J., McCrudden, M. T., & Donnelly, R. F. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.938635 · Cited by 174
DeMuth, P. C., Min, Y., Irvine, D. J., & Hammond, P. T. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300139 · Cited by 171
Biomaterial Strategies for Immunomodulation
Hotaling, N. A., Tang, L., Irvine, D. J., & Babensee, J. E. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104814 · Cited by 169
Releasing the Brakes on Cancer Immunotherapy
Littman, D. R. (2015) · Cell · doi:10.1016/j.cell.2015.08.038 · Cited by 166
Böhm, S., Montfort, A., Pearce, O. M. T., Topping, J. H., Chakravarty, P., Everitt, G. L. A., Clear, A. J., McDermott, J. R., Ennis, D. P., Dowe, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2657 · Cited by 162
Zhang, P., Chiu, Y.-C., Tostanoski, L. H., & Jewell, C. M. (2015) · ACS Nano · doi:10.1021/acsnano.5b02153 · Cited by 161
Why certain dyes are useful for localizing the sentinel lymph node.
Tsopelas, C., & Sutton, R. (2002) · PubMed · Cited by 157
Perica, K., Bieler, J. G., Schütz, C., Varela, J. C., Douglass, J., Skora, A. D., Chiu, Y., Oelke, M., Kinzler, K. W., Zhou, S., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b02829 · Cited by 153
Virus-mimetic nanovesicles as a versatile antigen-delivery system
Zhang, P., Chen, Y., Zeng, Y., Shen, C., Li, R., Guo, Z., Li, S., Zheng, Q., Chu, C., Wang, Z., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505799112 · Cited by 149
In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes
Zheng, Y., Stephan, M. T., Gai, S. A., Abraham, W. D., Shearer, A., & Irvine, D. J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.037 · Cited by 145
Biomaterials for enhancing anti-cancer immunity
Koshy, S. T., & Mooney, D. J. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.001 · Cited by 142
Liu, H., Kwong, B., & Irvine, D. J. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101266 · Cited by 140
Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres
Wang, X., Li, X., Ito, A., Watanabe, Y., Sogo, Y., Tsuji, N. M., & Ohno, T. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506179 · Cited by 138
Engineering opportunities in cancer immunotherapy
Jeanbart, L., & Swartz, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508516112 · Cited by 135
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
Yonezawa, A., Dutt, S., Chester, C., Kim, J., & Kohrt, H. E. K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0263 · Cited by 133
Targeting Nanoparticles to Dendritic Cells for Immunotherapy
Cruz, L. J., Tacken, P. J., Rueda, F., Domingo, J. C., Alberício, F., & Figdor, C. G. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-391858-1.00008-3 · Cited by 131
Biomimetic particles as therapeutics
Meyer, R. A., Sunshine, J. C., & Green, J. J. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.07.001 · Cited by 125
Storni, T., Lechner, F., Erdmann, I., Bächi, T., Jegerlehner, A., Dumrese, T., Kündig, T. M., Ruedl, C., & Bachmann, M. F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2880 · Cited by 125
Enhanced Cellular Activation with Single Walled Carbon Nanotube Bundles Presenting Antibody Stimuli
Fadel, T. R., Steenblock, E. R., Stern, E., Li, N., Wang, X., Haller, G. L., Pfefferle, L. D., & Fahmy, T. M. (2008) · Nano Letters · doi:10.1021/nl080332i · Cited by 119
Gu, L., Ruff, L. E., Qin, Z., Corr, M., Hedrick, S. Μ., & Sailor, M. J. (2012) · Advanced Materials · doi:10.1002/adma.201200776 · Cited by 117
Li, A. W., Lu, B., Gu, L., Choi, Y., Kim, J., & Mooney, D. J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.026 · Cited by 116
Alshamsan, A., Hamdy, S. I., Samuel, J., El‐Kadi, A. O. S., Lavasanifar, A., & Uludağ, H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.003 · Cited by 114
Advances in personalized cancer immunotherapy
Kakimi, K., Karasaki, T., Matsushita, H., & Sugie, T. (2016) · Breast Cancer · doi:10.1007/s12282-016-0688-1 · Cited by 112
Engineered materials for cancer immunotherapy
Cheung, A. S., & Mooney, D. J. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.007 · Cited by 111
Xu, L., Xiang, J., Liu, Y., Xu, J., Luo, Y., Feng, L., Liu, Z., & Peng, R. (2016) · Nanoscale · doi:10.1039/c5nr09208f · Cited by 111
Kosmides, A. K., Meyer, R. A., Hickey, J. W., Aje, K., Cheung, K. N., Green, J. J., & Schneck, J. P. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.038 · Cited by 111
Polymeric micro/nanoparticles: Particle design and potential vaccine delivery applications
Yue, H., & Ma, G. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.100 · Cited by 109
Lu, Y., Miao, L., Wang, Y., Xu, Z., Zhao, Y. D., Shen, Y., Xiang, G., & Huang, L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.165 · Cited by 109
Ligand-Conjugated Quantum Dots Monitor Antigen Uptake and Processing by Dendritic Cells
Cambi, A., Lidke, D. S., Arndt‐Jovin, D. J., Figdor, C. G., & Jovin, T. M. (2007) · Nano Letters · doi:10.1021/nl0700503 · Cited by 108
Vaccine delivery with microneedle skin patches in nonhuman primates
DeMuth, P. C., Li, A., Abbink, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2759 · Cited by 105
Liu, Y., Liang, X., Joo, K., Hu, B., Fang, J., & Wang, P. (2014) · Biomacromolecules · doi:10.1021/bm501166j · Cited by 103
Ali, O. A., Verbeke, C., Johnson, C., Sands, R. W., Lewin, S. A., White, D. A., Doherty, E. J., Dranoff, G., & Mooney, D. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0777 · Cited by 102
Bennewitz, N. L., & Babensee, J. E. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2004.08.023 · Cited by 101
Cruz, L. J., Rueda, F., Cordobilla, B., Simón‐Gracia, L., Hosta‐Rigau, L., Alberício, F., & Domingo, J. C. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100178k · Cited by 96
Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale
Rosenthal, J. A., Chen, L., Baker, J. L., Putnam, D. A., & DeLisa, M. P. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.11.005 · Cited by 95
Tian, Y., Zhang, J., Tang, S., Zhou, L., & Yang, W. (2015) · Small · doi:10.1002/smll.201503319 · Cited by 94
Adapting Cancer Immunotherapy Models for the Real World
Klevorn, L. E., & Teague, R. M. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.010 · Cited by 91
Synthetic biology in cell-based cancer immunotherapy
Chakravarti, D., & Wong, W. W. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.05.001 · Cited by 88
Immune-checkpoint blockade — durable cancer control
Buchbinder, E. I., & Hodi, F. S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.237 · Cited by 87
Wilson, N. S., Duewell, P., Yang, B., Li, Y., Marsters, S. A., Koernig, S., Latz, E., Maraskovsky, E., Morelli, A. B., Schnurr, M. M., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302011 · Cited by 82
Humoral immune responses to model antigen co-delivered with biomaterials used in tissue engineering
Matzelle, M. M., & Babensee, J. E. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00531-3 · Cited by 81
Nanoengineering Approaches to The Design of Artificial Antigen-Presenting Cells
Sunshine, J. C., & Green, J. J. (2013) · Nanomedicine · doi:10.2217/nnm.13.98 · Cited by 81
An iron age for cancer therapy
Tarangelo, A., & Dixon, S. J. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.199 · Cited by 81
Zhao, Y., Huo, M., Xu, Z., Wang, Y., & Huang, L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.053 · Cited by 80
Giannoni, F., Barnett, J., Bi, K., Samodal, R., Lanza, P., Marchese, P., Billetta, R., Vita, R., Klein, M. R., Prakken, B. J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3204 · Cited by 71
Carbon nanotubes as vaccine scaffolds
Scheinberg, D. A., McDevitt, M. R., Dao, T., Mulvey, J. J., Feinberg, E. N., & Alidori, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.013 · Cited by 71
Remote Control of T Cell Activation Using Magnetic Janus Particles
Lee, K., Yi, Y., & Yu, Y. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601211 · Cited by 71
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
Zheng, W., Skowron, K. B., Namm, J. P., Burnette, B., Fernandez, C., Arina, A., Liang, H. L., Spiotto, M. T., Posner, M. C., Fu, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9915 · Cited by 69
Cell Membrane-Coated Nanoparticles As an Emerging Antibacterial Vaccine Platform
Angsantikul, P., Thamphiwatana, S., Gao, W., & Zhang, L. (2015) · Vaccines · doi:10.3390/vaccines3040814 · Cited by 68
Ali, O. A., Tayalia, P., Shvartsman, D. E., Lewin, S. A., & Mooney, D. J. (2013) · Advanced Functional Materials · doi:10.1002/adfm.201203859 · Cited by 66
Liao, D., Liu, Z., Wrasidlo, W., Luo, Y., Nguyen, G., Chen, T., Xiang, R., & Reisfeld, R. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1264 · Cited by 64
Tang, J., Chen, Z., Sun, B., Dong, J., Liu, J., Zhou, H., Wang, L., Bai, R., Miao, Q., Zhao, Y., et al. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.11.021 · Cited by 64
Improving the clinical impact of biomaterials in cancer immunotherapy
Gammon, J. M., Dold, N. M., & Jewell, C. M. (2016) · Oncotarget · doi:10.18632/oncotarget.7304 · Cited by 64
Clustering of Stimuli on Single-Walled Carbon Nanotube Bundles Enhances Cellular Activation
Fadel, T. R., Look, M., Staffier, P. A., Haller, G. L., Pfefferle, L. D., & Fahmy, T. M. (2009) · Langmuir · doi:10.1021/la902068z · Cited by 60
Linking form to function: Biophysical aspects of artificial antigen presenting cell design
Perica, K., Kosmides, A. K., & Schneck, J. P. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.09.001 · Cited by 53
Faries, M. B., Bedrosian, I., Reynolds, C. A., Nguyen, H. Q., Alavi, A. A., & Czerniecki, B. J. (2000) · Annals of Surgical Oncology · doi:10.1007/s10434-000-0098-6 · Cited by 52
Molavi, O., Mahmud, A., Hamdy, S. I., Hung, R., Lai, R. L., Samuel, J., & Lavasanifar, A. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900145g · Cited by 48
Engel, A., Svane, I. M., Mouritsen, S., Rygaard, J., Clausen, J. T., & Werdelin, O. (1996) · Apmis · doi:10.1111/j.1699-0463.1996.tb04923.x · Cited by 48
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Chen, Q., Wang, C., Zhang, X., Chen, G., Hu, Q., Li, H., Wang, J., Wen, D., Zhang, Y., Lu, Y., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0319-4 · Cited by 1,010
Self-citationFunctional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment
Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., Jin, G., Lu, T. J., Genin, G. M., & Xu, F. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00094 · Cited by 825
Yang, R., Xu, J., Xu, L., Sun, X., Chen, Q., Zhao, Y., Peng, R., & Liu, Z. (2018) · ACS Nano · doi:10.1021/acsnano.7b09041 · Cited by 698
Wang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H., Hu, X., Liu, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3682 · Cited by 591
Self-citation
Metadata
- Authors
- Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2017-05-26
- Volume
- 29
- Issue
- 29
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2616983963
- Cited by
- 286
- References
- 209
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.